Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Common Equity (2021 - 2026)

Centessa Pharmaceuticals has reported Common Equity over the past 5 years, most recently at $526.9 million for Q4 2025.

  • Quarterly Common Equity rose 31.21% to $526.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $526.9 million through Dec 2025, up 31.21% year-over-year, with the annual reading at $526.9 million for FY2025, 31.21% up from the prior year.
  • Common Equity was $526.9 million for Q4 2025 at Centessa Pharmaceuticals, up from $301.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $526.9 million in Q4 2025 and troughed at $215.2 million in Q1 2024.
  • The 5-year median for Common Equity is $344.9 million (2025), against an average of $360.5 million.
  • Year-over-year, Common Equity surged 92.43% in 2024 and then tumbled 39.58% in 2025.
  • A 5-year view of Common Equity shows it stood at $491.6 million in 2021, then plummeted by 31.61% to $336.2 million in 2022, then dropped by 29.72% to $236.2 million in 2023, then skyrocketed by 69.97% to $401.5 million in 2024, then soared by 31.21% to $526.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Common Equity are $526.9 million (Q4 2025), $301.6 million (Q3 2025), and $344.9 million (Q2 2025).